Kyle Kuvalanka has been named the first chief operating officer of Cambridge, MA-based Syros Pharmaceuticals, a privately held startup developing so-called “gene control” drugs. Kuvalanka was previously the chief business officer of Blueprint Medicines (NASDAQ: BPMC), which went public and raised nearly $150 million in an IPO in April.
Xconomy Insight · Special Report
Industry experts explain what it takes to launch a new biotech company
From Our Editors · Podcast
Becoming the Cell & Gene Therapy Hub
Sponsored · Webinar
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX
